Dicerna Pharmaceuticals (DRNA) Reaches $8.25 After 5.00% Up Move; Profile of 5 Analysts Covering Saga PLC (LON:SAGA)

November 14, 2017 - By Hazel Jackson

Among 8 analysts covering Saga (LON:SAGA), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Saga had 94 analyst reports since August 26, 2015 according to SRatingsIntel. The stock of Saga PLC (LON:SAGA) has “Neutral” rating given on Friday, October 9 by Goldman Sachs. The stock of Saga PLC (LON:SAGA) has “Buy” rating given on Thursday, March 30 by Beaufort Securities. The firm has “Buy” rating by Peel Hunt given on Tuesday, November 3. The rating was downgraded by Canaccord Genuity to “Hold” on Tuesday, September 27. The firm earned “Add” rating on Wednesday, April 20 by Numis Securities. The stock of Saga PLC (LON:SAGA) earned “Neutral” rating by JP Morgan on Thursday, October 1. As per Thursday, March 17, the company rating was maintained by JP Morgan. UBS maintained the stock with “Neutral” rating in Friday, September 25 report. The firm has “Neutral” rating given on Wednesday, January 13 by Credit Suisse. The stock of Saga PLC (LON:SAGA) has “Buy” rating given on Thursday, September 22 by Beaufort Securities. See Saga PLC (LON:SAGA) latest ratings:

30/10/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 215.00 New Target: GBX 215.00 Maintain
24/10/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 215.00 New Target: GBX 215.00 Maintain
05/10/2017 Broker: Credit Suisse Rating: Neutral Old Target: GBX 220.00 New Target: GBX 210.00 Maintain
25/09/2017 Broker: Beaufort Securities Rating: Buy Maintain
22/09/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 240.00 New Target: GBX 240.00 Maintain
22/09/2017 Broker: Numis Securities Rating: Add Old Target: GBX 235.00 New Target: GBX 235.00 Maintain
20/09/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 250.00 New Target: GBX 240.00 Maintain
12/09/2017 Broker: Goldman Sachs Rating: Buy Old Target: GBX 230.00 New Target: GBX 230.00 Maintain
08/09/2017 Broker: JP Morgan Rating: Neutral New Target: GBX 215.00 Maintain
04/08/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 250.00 New Target: GBX 250.00 Maintain

The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a huge mover today! About 109,325 shares traded. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 5.22% since November 14, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.The move comes after 8 months positive chart setup for the $172.00 million company. It was reported on Nov, 14 by Barchart.com. We have $8.66 PT which if reached, will make NASDAQ:DRNA worth $8.60M more.

Saga plc is a provider of services for the clients aged 50 and over. The company has market cap of 2.07 billion GBP. The Firm operates through three divisions: Insurance, Travel, and Emerging Businesses and Central Costs. It has a 13.59 P/E ratio. Insurance segment consists of general insurance products, such as Motor insurance, Home insurance and Other insurance.

The stock increased 0.70% or GBX 1.28 on November 14, reaching GBX 184.88. About 1.20M shares traded. Saga PLC (LON:SAGA) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment decreased to 0.55 in 2017 Q2. Its down 0.40, from 0.95 in 2017Q1. It is negative, as 9 investors sold Dicerna Pharmaceuticals Inc shares while 11 reduced holdings. 4 funds opened positions while 7 raised stakes. 11.04 million shares or 3.09% more from 10.71 million shares in 2017Q1 were reported. Birchview Ltd Partnership reported 20,000 shares. Morgan Stanley holds 0% or 1,246 shares. Geode Cap Mgmt Ltd Liability Com reported 82,690 shares stake. Jpmorgan Chase & has invested 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Manufacturers Life Insurance The stated it has 642 shares or 0% of all its holdings. Panagora Asset Mngmt has 5,244 shares. Ecor1 Llc has 767,992 shares. Renaissance Techs Ltd Liability Co stated it has 443,100 shares. Savings Bank Of America Corp De has 35 shares for 0% of their portfolio. Dimensional Fund Advisors Limited Partnership stated it has 32,024 shares. California-based California Employees Retirement Sys has invested 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Blackrock Inc has invested 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Qs Ltd Co stated it has 1,071 shares or 0% of all its holdings. Vanguard Group holds 340,327 shares or 0% of its portfolio. Barclays Public Limited Company stated it has 78 shares.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals has $30 highest and $3.50 lowest target. $9.88’s average target is 19.76% above currents $8.25 stock price. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Tuesday, July 18. The company was maintained on Friday, August 11 by H.C. Wainwright. On Thursday, November 2 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock has “Neutral” rating by Chardan Capital Markets on Thursday, June 30. On Tuesday, January 31 the stock rating was reinitiated by Leerink Swann with “Mkt Perform”. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, November 11. The firm has “Outperform” rating by Cowen & Co given on Tuesday, September 8. H.C. Wainwright initiated Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Monday, December 12 with “Buy” rating. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has “Buy” rating given on Wednesday, August 16 by Cowen & Co. The company was maintained on Tuesday, May 10 by Stifel Nicolaus.

Analysts await Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to report earnings on March, 29. They expect $-0.64 earnings per share, up 5.88% or $0.04 from last year’s $-0.68 per share. After $-0.92 actual earnings per share reported by Dicerna Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -30.43% EPS growth.

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid interference biopharmaceutical company. The company has market cap of $172.00 million. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It currently has negative earnings. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com